Heart failure & cardiomyopathies
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
Authors' conclusion
In patients with HF with mildly reduced or preserved ejection fraction, finerenone reduced the risk of cardiovascular death and worsening HF events, irrespective of LVEF.
Study context
- Population
- Patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥40% (mildly reduced or preserved EF)LVEF available for 5993
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo, by LVEF
- Primary endpoint
- Composite of:
- Total (first and recurrent) worsening HF events
- CV death
Methodological detailsplacebo-controlled, prespecified analysis by LVEF
- Placebo-controlled
- Prespecified analysis by LVEF
Primary result
As reported in the abstract
Finerenone vs PlaceboRate ratio (95% CI)
LVEF <50% (n = 2172)
0.84(0.68–1.03)
LVEF ≥50% to <60% (n = 2674)
0.80(0.66–0.97)
LVEF ≥60% (n = 1147)
0.94(0.70–1.25)
- No modification of benefit across LVEF as a continuous variable
- P for interaction = 0.28
Further findings
Total worsening HF events, by LVEF
- Similar consistent effect of finerenone across LVEF
- continuous Pinteraction=0.26
Baseline LVEF
- Mean LVEF
- 53±8%
- Median LVEF (IQR 46%-58%)
- 53%
Original publication
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. Published 29 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →